Address local barriers to ensure appropriate access to treatment for
lowering LDL-C, especially for high and very high-risk patients
Systemically measure treatment to goal as a management metric to
better drive diagnosis and treatment
Initiate dialogs with various stakeholders to approach innovative
purchasing mechanisms including managed entry agreements, pooled
procurement, and risk sharing schemes, among others
Include Medical-Scientific Societies in the decision-making process
related to the appropriate use of lipid-lowering therapy and ASCVD
prevention
- Inform the public regarding the importance of ASCVD prevention to
control severe risk with widely broadcasted primary preventive programs